secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADC Therapeutics SA (ADCT)
CIK:        0001771910
Form:       8-K
Filed at:   2025-10-14T23:59:59+00:00
Accession:  0000950103-25-013103
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 2.02, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ADC Therapeutics raises $60M PIPE; prelim Q3 ZYNLONTA revenue $15.8M, cash $234.7M
--------------------------------------------------------------------------------

- PIPE of 11.25M shares at $4.00 and 3.85M pre-funded warrants at $3.90; gross $60M, close expected Oct 27.
- Preliminary Q3 2025 ZYNLONTA net product revenue approximately $15.8M.
- Cash and equivalents $234.7M as of Sep 30; pro forma $292.3M after PIPE net proceeds (~$57.6M).
- PIPE led by TCGX with Redmile Group and other existing investors; Jefferies acted as placement agent.
- Net proceeds to fund ZYNLONTA commercial expansion, strengthen balance sheet, and working capital.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1771910/000095010325013103/0000950103-25-013103-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1771910/000095010325013103/dp235779_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950103-25-013103

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer